NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

NeuroSense Therapeutics Ltd. , today announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis (ALS) conducted by Dr. Justin Ichida, PhD at the University of Southern California’s (USC) Stem Cell Ichida Lab, part of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC.